These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 36241457)
1. [Assessment of the pain induced by vaccination according to the injected arm (COVID-19 vaccination)]. Barreau A; Boivin AH; Castaing B; Brault P; Darraillans N; Auvet A; Dimet J Rech Soins Infirm; 2022; 149(2):78-84. PubMed ID: 36241457 [TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
3. Traditional Chinese medicine auricular point acupressure for the relief of pain, fatigue, and gastrointestinal adverse reactions after the injection of novel coronavirus-19 vaccines: a structured summary of a study protocol for a multicentre, three-arm, single-blind, prospective randomized controlled trial. Fu Q; Xie H; Zhou L; Li X; Liu Y; Liu M; Wang C; Wang X; Wang Z; Tang J; Xiao H; Xiao Z; Zhou J; Feng C; Wang L; Ao Z; Chen X; Su C; Wu X; Zhao M; Hu S; Lin H; Huang J; Xu G; Zhang Q; Jiang L Trials; 2021 Feb; 22(1):162. PubMed ID: 33632286 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial. Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461 [TBL] [Abstract][Full Text] [Related]
5. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany. Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480 [TBL] [Abstract][Full Text] [Related]
6. Safety of SARS-CoV2 vaccination and COVID-19 short-term outcome in pediatric acquired demyelinating disorders of central nervous system: A single center experience. Monte G; Papetti L; Ferilli MAN; Ursitti F; Moavero R; Sforza G; Panella E; Tarantino S; Checchi MP; Vigevano F; Palma P; Valeriani M Front Immunol; 2023; 14():1106472. PubMed ID: 36761740 [TBL] [Abstract][Full Text] [Related]
7. Side effects after COVID-19 vaccinations among residents of Poland. Andrzejczak-Grządko S; Czudy Z; Donderska M Eur Rev Med Pharmacol Sci; 2021 Jun; 25(12):4418-4421. PubMed ID: 34227078 [TBL] [Abstract][Full Text] [Related]
8. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185 [TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
10. Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines. Zhang R; Leung KY; Liu D; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF mSphere; 2022 Apr; 7(2):e0091521. PubMed ID: 35285250 [TBL] [Abstract][Full Text] [Related]
11. Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers. Maruyama A; Sawa T; Teramukai S; Katoh N J Infect Chemother; 2022 Jul; 28(7):934-942. PubMed ID: 35361536 [TBL] [Abstract][Full Text] [Related]
12. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial. Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]. Poh XY; Lee IR; Lim C; Teo J; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Ng LFP; Ren EC; Lin RTP; Wang LF; Renia L; Lye DC; Young BE Trials; 2022 Jun; 23(1):498. PubMed ID: 35710572 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial. Li G; Cappuccini F; Marchevsky NG; Aley PK; Aley R; Anslow R; Bibi S; Cathie K; Clutterbuck E; Faust SN; Feng S; Heath PT; Kerridge S; Lelliott A; Mujadidi Y; Ng KF; Rhead S; Roberts H; Robinson H; Roderick MR; Singh N; Smith D; Snape MD; Song R; Tang K; Yao A; Liu X; Lambe T; Pollard AJ; Lancet; 2022 Jun; 399(10342):2212-2225. PubMed ID: 35691324 [TBL] [Abstract][Full Text] [Related]
15. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older. Choi YY; Kim MK; Kwon HC; Kim GH J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980 [TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM; Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274 [TBL] [Abstract][Full Text] [Related]
17. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data. Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939 [TBL] [Abstract][Full Text] [Related]
18. Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE). Tran AP; Tassone D; Nossent J; Ding NS RMD Open; 2022 May; 8(1):. PubMed ID: 35577478 [TBL] [Abstract][Full Text] [Related]
19. Various painful oral adverse reactions following COVID-19 vaccination: a case series. Chun Y; Jang J; Jo JH; Park JW BMC Oral Health; 2022 Mar; 22(1):64. PubMed ID: 35260129 [TBL] [Abstract][Full Text] [Related]
20. Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of Rheumatologists. Santosa A; Xu C; Arkachaisri T; Kong KO; Lateef A; Lee TH; Leong KH; Low AHL; Sriranganathan MK; Tan TC; Teng GG; Thong BY; Fong W; Lahiri M Int J Rheum Dis; 2021 Jun; 24(6):746-757. PubMed ID: 33973379 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]